In this study we compared side-by-side the anti-neoplastic activity of the oncolytic herpes simplex virus-1 (HSV-1) vector G47D with that of a conditionally replicative adenoviral vector for the treatment of glioblastoma. We analyzed the transduction efficiency of permanent glioblastoma cell lines and short-term cultures of glioblastoma cells with HSV.Luc and four adenovirus type 5 (Ad5)-based vectors that differed only in their fiber gene (Ad5.Luc, AdlucRGD, and the fiber chimeric vectors Ad5/3.Luc and Ad5/35.Luc). In the tested short-term cultures of glioblastoma cells the vectors Ad5/35.Luc and HSV.Luc had an equal transduction efficiency which was B70% higher than that of Ad5.Luc. In a subcutaneous xenograft glioblastoma model in nude mice we observed a significantly higher local tumor control with the G47D vector compared to the conditionally replicative Ad5/35 adenovirus. We confirmed in glioblastoma that the intratumoral expression of measles virus fusogenic membrane glycoproteins (FMG) encoded by replication-defective Ad5/35 or HSV-1 amplicon vectors synergistically enhances chemotherapy with temozolomide. The antineoplastic effect was superior when the replication-defective FMG encoding vectors were trans-complemented for replication with the respective oncolytic vector. This approach was necessary due to packaging constraints of adenovirus. At day 100, of 6 treated animals 1 was alive that received the Ad5/35-and 3 that received the HSV-1-based triple therapy. In an intracranial glioblastoma xenograft model we demonstrated the applicability of this strategy. Due to the higher oncolytic efficacy and packaging capacity of the HSV-1 vectors compared to adenovirus, these vectors are promising for the treatment of glioblastoma.
Introduction
Although malignant gliomas generally remain localized to the brain, advanced glioblastoma multiforme (GBM) is incurable despite surgery, radiotherapy, and chemotherapy due to its infiltrative nature and cytological heterogenicity. 1 GBM represents an excellent target for novel treatment strategies such as gene therapy and virotherapy partly due to the enhanced possibility of tumor-specific targeting since brain tumors are unifocal and glioblastoma cells are among the few rapidly proliferating ones in the CNS, where only some microglia and endothelial cells have the ability to divide. Furthermore, as the tumor's fatality is mainly caused by local growth and local recurrence, therapeutic activity is only needed locally and in dividing cells.
Up to now the treatment of glioblastoma with oncolytic viruses chiefly utilized the neurotropic human herpes simplex virus type 1 (HSV-1). Wild-type HSV can invade and replicate in both neurons and glia, resulting in necrotizing encephalitis and widespread hemorrhagic necrosis throughout infected brain parenchyma. Therefore genetically engineered HSV-1 lack the ability to replicate in normal neurons, but retain the ability to replicate in and destroy tumor cells, including gliomas and other brain tumors. 2, 3 These engineered viruses lack neurotoxicity by deletion of both copies of the g34.5 genes 4 and replication in non-dividing cells is precluded by inactivation of ICP6, the large subunit of ribonucleotide reductase, a key enzyme for nucleotide metabolism and viral DNA synthesis. 5 Clinical trials in glioblastoma patients with direct stereotactic intratumoral injections of these engineered HSV-1, designated G207 and HSV1716, revealed that these viruses are safe, but also that the oncolytic efficacy as single agent is limited. 6, 7 Furthermore human adenoviruses have often been used as oncolytic agents, primarily of non-neuronal malignancies. 8 Adenoviruses infect a wide variety of cells and often cause in humans acute mucous-membrane infections of the upper respiratory tract, eyes and regional lymph nodes, resembling the common cold. For the treatment of glioblastoma dl1520 (ONYX-015), an E1B-55k-deleted adenovirus type 5 (Ad5) has been evaluated. 9 It is thought that ONYX-015 replicates more efficiently in cells with dysfunction p53 pathway, 10 although this mechanism remains controversial. [11] [12] [13] [14] [15] [16] However due to the E1B-55k-deletion the oncolytic efficacy of this virus is lower than that of parental adenovirus. 17 Controlled clinical trials using ONXY-015 for a variety of cancers revealed low toxicity, and disappointing efficacy as single-agent treatment but in combination with chemotherapy encouraging anti-neoplastic activity. [18] [19] [20] [21] [22] The primary goal of this study was to compare side-by side the anti-neoplastic efficacy of the engineered oncolytic HSV-1 G47D, a G207 derivative, 23 with that of a conditionally replicative adenovirus for the treatment of glioblastoma xenografts.
Since in most glioblastoma the glial fibrillary acidic protein (GFAP) and the proliferation marker pKi67 is detectable, 24 we generated a conditionally replicative adenovirus vector for glioblastoma therapy by placing the viral E1A and E4 genes, which are essential for viral replication, under the transcriptional control of the GFAP promoter without silencer and E4 under the control of the proliferation-associated Ki67 promoter. Several groups demonstrated that controlling the expression of E1A and E4 genes simultaneously will provide a significantly tighter control over virus replication than just transcriptionally targeting of E1A. [25] [26] [27] [28] [29] [30] Because the anti-neoplastic efficacy of oncolytic adenoviral vectors is critically dependent on the expression of the primary adenovirus receptor on the tumor cells 31, 32 and the capacity of Ad5-based vectors to infect human glioblastoma cells has been questioned by several groups, [33] [34] [35] [36] [37] we bypassed the dependence on coxsackie adenovirus receptor (CAR) for adenoviral entry by using the fiber chimeric Ad5/35, which uses CD46 as primary receptor 38, 39 which is overexpressed by malignant glioma. 40 We named the conditionally replicative adenovirus for glioblastoma therapy Ad5/35.GD Á Ki.
For cancer gene therapy Bateman et al. introduced fusogenic membrane glycoproteins as a new class of therapeutic genes and demonstrated that fusogenic membrane glycoproteins (FMG) expression alone resulted in a significantly greater tumor growth control than the suicide prodrug systems. 41, 42 Intratumoral expression of viral fusogenic glycoproteins lead to syncytia formation of infected cells with adjacent cells, thereby increasing the dispersion of viruses throughout the tumor, 43 lateral spread of the transgene, virus release 44 and enhanced immunogenicity of tumor cells. 45, 46 For cancer gene therapy, glycoproteins from human immunodeficiency virus (HIV-1), 44 gibbon ape leukemia virus (GALV), 42, 47 and measles virus 48 have been evaluated. To enhance the treatment efficacy of oncolytic vectors we combined viral oncolysis with the intratumoral expression of measles virus fusogenic membrane glycoproteins H and F (FMG) and temozolomide chemotherapy, since we demonstrated in previous studies in colorectal and pancreatic cancer cell lines that the expression of FMG synergistically enhances the cytotoxicity of clinically relevant chemotherapy and significantly improves therapeutic outcome in vivo. 49, 50 In combination with oncolytic vectors this triple therapy, consisting of FMG expression, chemotherapy and viral oncolysis, had a significantly greater anti-neoplastic efficacy than treatment with its compounds as single or double agent therapy. 49, 50 Since the FMG expression cassette exceeds the packaging capacity of replication-competent adenoviral vectors, 51 we trans-complemented the replication-defective adenovirus vector encoding the FMG with the conditionally replicative adenovirus Ad5/35.GD Á Ki. In cells transduced with both, the replication-defective vector encoding FMG and the replication-competent oncolytic vector, the replication-defective vector will be trans-complemented to allow vector amplification and intratumoral spread resulting in improved tumor transduction.
52-58 For comparison we used the same approach for HSV-1, despite the fact that we have generated an oncolytic HSV-1 expressing FMG.
In this study we evaluated the anti-neoplastic efficacy of a conditionally replicative adenovirus Ad5/35.GD Á Ki with that of the engineered HSV-1 G47D in a subcutaneous and intracranial xenograft glioblastoma tumor model in nude mice alone or in combination with the intratumoral expression of fusogenic membrane glycoproteins and/or temozolomide chemotherapy. We used the glioblastoma cell line U251, since this cell line is the only permanent glioblastoma cell lines that has not lost GFAP expression. 59 To our knowledge, this is the first report comparing side-by-side the oncolytic efficacy of a conditionally replicative Ad5/35 and HSV-1-based vector, alone or in combination with viral fusogenic glycoproteins and/or chemotherapy for the treatment of glioblastoma.
Materials and methods

Cells and cell culture
The permanent human glioblastoma cell lines U87 (ATCC HTB-14) and the human lung carcinoma cell line A549 (ATCC CCL-185) were obtained from the ATCC (Manassas, VA). The human glioblastoma cell lines U251 and D54 were a gift from Darrell Bigner, Duke University Medical Center, Durham, NC. The human embryonic kidney cell line 293 was obtained from Microbix Biosystems, Inc. (Toronto, ON). We established shortterm cultures of glioblastoma cells, designated PGBM1 and PGBM2 from patients with histologically confirmed glioblastoma multiforme as described previously for other tumor entities. 30 Glioblastoma resection specimens were kindly provided by Bernhard Meyer, Friedrich-WilhelmsUniversity Bonn, Department of Neurosurgery, Germany. Ethical clearance was obtained from the local Ethics Committee (Reg. No. 2487). Cells were cultured in D-10, consisting of Dulbecco's modified Eagle medium with high glucose (Invitrogen/Gibco, Karlsruhe, Germany), supplemented with 10% heat-inactivated fetal bovine serum and 50 mg/ml gentamicin. Primary human keratinocytes (HKC) were kindly provided by Kerstin Reimers (Klinik fu¨r Plastische Hand-und Wiederherstellungschirurgie, MHH, Hannover, Germany) and propagated in PromoCell Keratinocyte Growth Medium 2 (Promocell GmbH, Heidelberg, Germany).
Viral vectors
In the conditionally replicative adenovirus Ad5/ 35.GD Á Ki, the E1A and E4 region, which is essential for viral replication, is under the transcriptional control of the promoter of the glial fibrillary acidic protein without the silencer (À1821yÀ1023/À433y þ 47; generated from the plasmid pGfa2-cLac, 59 kindly provided by Michael Brenner, UAB, Neurobiology, Birmingham, AL) and the proliferation associated Ki67 promoter (À600/ þ 7). Adenovirus plasmid vector was generated in a single homologous recombination step in E. coli as described previously 60 The replication-defective firefly luciferase encoding adenoviral vectors Ad5.Luc, Ad5/3.Luc and Ad5lucRGD have been described previously. 62 In addition we generated Ad5/35.Luc by homologous recombination with the Ad5 backbone plasmid pAdEasy-1/F35 and subsequent rescue of infectious vector in 293 cells as described previously. 63 All luciferase encoding adenoviral vectors differed only in the fiber gene and were propagated in 293 cells.
The Ad5/35 fiber chimeric Ad5-based replicationdefective adenoviral vector Ad5/35.H/F carries a bicistronic expression cassette H/IRES/F 64 (kindly provided by Roberto Cattaneo, Rochester, MN) under the transcriptional control of the tumor-specific human telomerase reverse transcriptase promoter (hTERT À548/ þ 5), which has been evaluated in a transcriptionally E1A targeted oncolytic adenovirus for glioblastoma therapy. 37 The vector was generated via homologous recombination in E. coli using pAdEasy-1/F35, 61 rescued and propagated in 293 cells. Analogous the replicationdefective GFP encoding Ad5/35.GFP vector was generated using the previously described shuttle plasmid. 65 Adenovirus vectors were purified with the Vivapure AdenoPACK 100 kit (Vivascience, Hannover, Germany). The adenoviral particle concentration in purified preparations was determined by spectrophotometry as described previously 66 and expressed as viral particles (VP)/ml. The infectious titer was determined by plaque assay using 293 cells or indicated cell line and expressed as plaque forming units (PFU). 66 With the ion-exchange column purification kit we obtained constant particle-to-PFU ratios of B30:1.
The replication-restricted oncolytic HSV-1 G47D 50 The helper-virus free HSV.H/F amplicon vector encoding measles virus fusogenic membrane proteins H and F under the transcriptional control of the tumor-specific human telomerase reverse transcriptase gene promoter (hTERT À548/ þ 5). 67 The vectors Ad5/35.H/F and HSV.H/F were generated and produced in the presence of the synthetic fusion inhibitory peptide Z-D-Phe-Phe-Gly-OH (10 mM; Bachem AG, Bubendorf, Switzerland). All HSV-based vectors were purified by ultracentrifugation through a 40% sucrose cushion, resuspended in PBS in 1/100 of the original volume and concentrated virus particles were centrifuged through a 20-35% nycodenz (Sigma-Aldrich, Munich, Germany) step gradient. The virus band at the gradient junction was collected. The activities of the oncolytic adenoviral vectors and the G47D vector were determined on indicated the same panel of cells by plaque assay.
Determination of glioblastoma transduction efficiency with adenovirus and HSV-1 Cells were seeded at a concentration of 5 Â 10 3 cells/well in 100 ml into flat bottom 96-well culture plates. Twelve hours later, cell monolayers were transduced with 5 Â 10 3 VP/well of four firefly luciferase encoding Ad5-based vectors (Ad5.Luc, Ad5lucRGD Ad5/3.Luc, and Ad5/35.Luc) that differed only in their fiber gene. This dose of Ad5.Luc was equivalent to 1.6 Â 10 2 PFU/well (determined on 293 cells) and resulted in B30% of the maximum obtainable luciferase activity in A549 or 293 cells. The ED 30 was chosen to minimize double transductions and saturation effects. To compare the transduction efficiency of the adenoviral vectors with that of HSV-1, the infectious titer of HSV-1 was determined on 293 cells and normalized to that of Ad5.Luc. Thus, cell monolayers were transduced with HSV.Luc at a multiplicity of infection of 1.6 Â 10 2 PFU/well (determined on 293 cells). Twenty-four hours post transduction cell monolayers were washed with PBS and luciferase assay was carried out and normalized to total protein amount, measured by the Bradford protein assay (BioRad, Hercules, CA) according to the manufacture's instructions.
Analysis of combined drug effects
We quantitatively analyzed the interaction between measles virus fusogenic membrane expression and temozolomide in glioblastoma cells using the medianeffect principle. 68, 69 
A CIo1 indicates synergy, while a CI ¼ 1 shows an additive effect, and CI41indicates antagonism. 69 In this equation, the dose reduction index (DRI) defines the extent of drug dose reduction possible in a combination for a given degree of effect as compared with the dose of each drug alone. 69 When the concentration-effect relationship follows the principle of mass action, the medianeffect plot should be linear. Linear correlation coefficients (r) were generated for each curve to determine the applicability of the data to this method of analysis. In all synergy experiments r was 40.9.
Thirty six hours after treatment, the cytotoxic effects in U87, U251, PGBM1 and PGBM2 cells was analyzed using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI), as recommended by the manufacturer.
Cell cycle arrest and analysis Cells were arrested at the beginning of S phase by incubation with 2 mM thymidine and 1 mg/ml aphidicolin 70 (Sigma-Aldrich) 8 h after transfection or at the time of adenovirus infection until analysis. Cell cycle distribution was determined by flow cytometric analysis (FACSCalibur flow cytometer, Becton Dickinson Immunocytometry Systems, Mansfield, MA), as described previously. 71 
Animal studies
For the subcutaneous xenograft model, six to eight week-old female athymic Balb/c nu/nu mice (Janvier, Le Genest-St-Isle, France) received subcutaneously 1 Â 10 7 U251-Luc3 cells in 100 ml into the hind flanks. When the tumors reached a volume of B200 mm 3 , animals were randomly assigned to treatment groups (n ¼ 8 8 PFU (determined on U251 cells) alone or in combination with temozolomide. All viral vectors were administered intratumorally on day 0 and day 2 in a total volume of 100 ml PBS. At least once a week, minimum and maximum perpendicular tumor axes were measured using vernier calipers, and tumor volume was calculated using the formula l Â w 2 Â 0.5. The skin thickness of 0.4 mm was subtracted from the measurements.
For the intracranial glioblastoma xenograft model eight week-old female Balb/c nu/nu mice (Janvier) were anesthetized (ketamine/xylazine 190 and 24 mg/kg i.p., respectively) and immobilized in a Cunningham mouse adaptor (Stoelting, Wood Dale, IL). A 5-mm skin incision was made along the sagittal suture. Animals were then placed in a model E51600 stereotactic frame (Stoelting) and a burr hole was drilled with a 25-gauge needle into the skull 2 mm lateral and 1 mm anterior to the bregma. U251-Luc3 tumor cells (2 Â 10 5 cells/mouse) suspended in 5 ml of PBS were injected in 2.5 mm depth from the dura into the right caudate nucleus using a 30-gauge 10-ml Hamilton syringe mounted on a motorized stereotactic injector over 5 min. Six days later, animals were randomly assigned to treatment groups (n ¼ 6). Two animals of each group underwent bioluminescence imaging to confirm intracranial tumor formation at this time point. Seven days after tumor cell inoculation animals were treated with 5 Â 10 4 PFU (determined on U251 cells) of the measles virus H and F encoding vector (Ad5/35.H/F or HSV.H/F) plus 5 Â 10 4 PFU (determined on U251) of the respective trans-complementing replication-restricted oncolytic vector (Ad5/35.GD Á Ki or G47D) delivered in 3 ml to the tumor coordinates. Viral vectors were given over a period of 10 min in order to increase transduction efficiency and spatial distribution. Burr holes were sealed with bone-wax and the incision closed with stainless steel wound clips. In both tumor models, temozolomide (5 mg/kg/day) was given intraperitoneally once a day for 4 consecutive days starting on day 4 in 2 ml 0.9% NaCl solution.
Quantitative HSV-1 PCR We determined the copy number of G47D in serum samples of animals before and after treatment using a qPCR assay. DNA was isolated using the QIAamp DNA Blood Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The HSV-1/-2 LightCycler PCR has been described previously. 72 The detection limit was 800 copies of G47D per ml serum.
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Bioluminescence imaging To analyze intracranial tumor growth, nude mice were anesthetized (ketamine/xylazine, 4:1), and the substrate K þ D-luciferin (150 mg/kg body weight; BD, Mansfield, MA) was injected intraperitoneally 10 min before imaging with a photon counting system (Hamamatsu Photonics, Herrsching am Ammersee, Germany). An integration time of 10 min was used for luminescent image acquisition using the HPD-LIS 2.6 software (Hamamatsu).
Statistical methods and median-effect analysis
The statistical software package SPSS 13 (SPSS Inc., Chicago, IL) was used for data analysis with indicated tests. Analysis of combined effects of multiple agents, described by Chou & Talalay, 69 was done with the software CalcuSyn 2.0 (Biosoft, Cambridge, UK).
Results
The transduction efficiency of glioblastoma cells was the highest with Ad5/35.Luc and HSV.Luc First we determined the transduction efficiency of permanent glioblastoma cell lines (U87, U251 and D54) and short-term cultures of glioblastoma cells (PGBM1 and PGBM2) with HSV-1 (HSV.Luc) and adenovirus. Since the capacity of Ad5 to infect human glioblastoma cells have been challenged by several groups, 33, 34 we evaluated four firefly luciferase encoding Ad5-based vectors (Ad5.Luc, Ad5lucRGD, Ad5/3.Luc, and Ad5/ 35.Luc) that differed only in their fiber gene. The multiplicity of infection (MOI) of HSV.Luc and Ad5.Luc was normalized by plaque titration on 293 cells. Since all fiber-modified Ad5-based luciferase vectors used different cellular receptors for attachment, we then normalized these vectors by viral particle numbers to Ad5.Luc. With the adenovirus ion-exchange column purification kit we obtained constant particle-to-PFU ratios of B30:1.
As shown in Figure 1 , all tested adenoviral vectors can efficiently transduce tested glioblastoma cells. However, compared to Ad5.Luc the transduction of permanent glioblastoma cell lines with Ad5/35.Luc, Ad5lucRGD , Ad5/3.Luc, and HSV.Luc was enhanced 1.2-, 1.1-, 3.7-, and 3.1-fold, respectively. In short-term glioblastoma cell cultures, the mean transduction efficiency was improved with these fiber modified vectors 1.9-, 1.7-, 3.7-, and 3.4-fold, respectively, when compared to the parental Ad5 vector. To improve the readability we pooled the data instead of presenting individual cell lines. The transduction efficiency of short-term glioblastoma cultures was the highest with the Ad5/35.Luc and HSV.Luc vector (Po0.05, ANOVA with Newman-Keuls multiple comparison test). There was no significant difference in the transduction efficiency of Ad5/35.Luc and HSV.Luc. Infection of tested proliferating glioblastoma and nonglioblastoma cells with G47D resulted at an MOIX0.5 in complete cell lysis. In contrast, infection of arrested cells with G47D did not result in a detectable cytopathic effect at an MOIp10.
Cytopathic effect assay
Synergy between FMG expression and chemotherapy in vitro
Previously we demonstrated in colorectal and pancreatic cancer cell lines that the expression of measles virus fusogenic membrane glycoproteins H and F (FMG) in combination with clinically relevant chemotherapy results in an synergistically enhanced cytotoxicity. 49, 50 Since glioblastoma are notoriously resistant to chemotherapy, we analyzed whether the expression of FMG in 66 was calculated based on the assumption that one plaque forming unit equals one biologically active virion. This provided the basis for the appropriate ratio of Ad5/35.H/F and temozolomide. The ratio was kept constant when the agents were studied in combination. The interaction of the agents was analyzed with the software CalcuSyn, providing two parameters, the combination index (CI) and the dose reduction index (DRI). The dose-effect curves and combination index plots are shown in Figure 3 . In the combination index plots, values above 1 indicate antagonistic drug effects, whereas those below 1 are considered synergistic. A combination index of 1 suggests additive effects of both agents. The effects of drug combinations on the ED 50 concentrations are shown in Table 2 . We observed the highest dose reduction index for temozolomide in U251 transduced with Ad5/35.H/F. The dose of Ad5/35.H/F and temozolomide needed to achieve the ED 50 was reduced 9.3-and 6875.3-fold, respectively, compared to single agent treatment ( Table 2) .
Since permanent cell lines have often been in continuous culture for several years and thus are likely to have genetic aberrations, we verified our data in short-term cultures of primary glioblastoma cancer cells (Figure 3) . In both short-term cultures of glioblastoma cells (PGBM1 and PGBM2), the expression of FMG and temozolomide resulted in synergistically enhanced cytotoxicity. To rule out that this effect was caused by adenovirus gene products, we used as control a replication-defective adenovirus encoding GFP (Ad5/35.GFP). As shown in Figure 3b and d transduction of U251 with Ad5/35.GFP in combination with temozolomide had no additive or synergistic effect on the chemotherapy. We obtained the same data for the other tested permanent cell lines or short-term cultures (data not shown).
Superior efficacy of the HSV-1-based treatment regimen over homologous adenovirus-based treatment regimen
In a subcutaneous U251-Luc3 glioblastoma xenograft model we analyzed side-by-side the anti-neoplastic activity of the conditionally replicative adenovirus Ad5/ 35.GD Á Ki and the multi-mutated HSV-1 vector G47D.
Secondly we evaluated whether the expression of measles virus fusogenic membrane proteins in combination with temozolomide results in an enhanced in vivo treatment efficacy when compared to single agent therapy. Since replication-defective vectors are associated with poor tumor transduction efficiency and replication-competent [52] [53] [54] [55] [56] [57] [58] In the subcutaneous glioblastoma model untreated animals had a median survival of 29 days. Mice that received temozolomide or intratumoral injection of the replication-defective FMG encoding vector Ad5/35.H/F had a median survival of 33 and 37 days, respectively (Figure 4a ). Animals that received Ad5/35.H/F in combination with temozolomide had a median survival of 41 days. Kaplan-Meier survival analysis with MantelCox log-rank test revealed that the combination of FMG expression and chemotherapy was significantly better than single agent therapy with its components (Pp0.04). In a pilot experiment we obtained similar data with HSV.H/F alone and in combination with temozolomide (data not shown). a The DRI (dose reduction index) determines the magnitude of dose reduction allowed for each drug when given in synergistic combination, as compared with the concentration of a single agent that is needed to achieve the same effect level.
Animals treated with the oncolytic vectors Ad5/ 35.GD Á Ki or G47D had a median survival time of 48 and 59 days, respectively (Pp0.001, Mantel-Cox log-rank test) (Figure 4b and c) . The combination of oncolytic vector and temozolomide resulted in a significantly enhanced median survival of 54 and 63 days, respectively (Pp0.001, Mantel-Cox log-rank test). The combination of FMG expression (encoded by Ad5/35.H/F or HSV.H/F) and respective trans-complementing oncolytic vector resulted in a significantly enhanced median survival of 62 and 73 days, respectively (Pp0.001, Mantel-Cox logrank test). The combination of FMG expression, transcomplementing oncolytic vector and temozolomide resulted in a median survival time of 72 and 83 days, respectively. The adenovirus and HSV-1-based triple therapy was significantly more effective than any combination of its respective compounds as single or double agent therapy (Pp0.001, Mantel-Cox log-rank test), with one of 8 animal alive at day 100 in the adenovirus-and three of 8 in the HSV-1-based triple therapy treatment group. There were no long-term survivors in any of the other treatment groups. The treatment efficacy of the HSV-1-based triple therapy was significantly higher than the corresponding adenovirus-based triple therapy (Pp0.001, Mantel-Cox log-rank test). Due to the high sensitivity of the brain to damage we determined whether it is feasible to apply the adenovirus or HSV-1-based triple therapy consisting of measles virus FMG expression, trans-complementing oncolytic virus and temozolomide, for the treatment of intracranial glioblastoma xenografts.
In the intracranial xenograft model, untreated mice had a median survival of 27 days (Figure 5a ). For comparison we included one treatment group that received temozolomide as single agent therapy, the first-line treatment for advanced glioblastoma. These animals had a significantly improved median survival of 35 days (Pp0.001, MantelCox log-rank test). When compared to single agent temozolomide treatment, animals that received the adenovirus or HSV-1-based triple therapy had a significantly improved median survival of 78 and 80 days, respectively (Pp0.001, Mantel-Cox log-rank test). At day 80, the end of the observation period, 4 of the 6 animals treated with the adenovirus based triple therapy were alive and 6 of the 6 animals treated with the HSV-1-based triple therapy were alive. The treatment efficacy of the HSV-1-based treatment regimen was significantly higher than that of the adenovirus based triple therapy (Pp0.001, Mantel-Cox log-rank test).
Since we used for the glioblastoma xenograft model constitutively firefly luciferase expressing U251-Luc3 cells, we evaluated tumor growth also by noninvasive in vivo bioluminescence imaging. As shown in Figure 5b , we confirmed intracranial tumor growth one day before treatment (day-1). The luciferase activity at day 21 of all treatment groups was clearly reduced, indicating smaller tumors compared with untreated animals. At day 80 all animals treated with the triple combination therapy were tumor-free by bioluminescence imaging. The intracranial detection limit was 5000 luciferase expressing cells. 
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None of the animals died due to treatment related toxicity. One animal of each treatment group underwent histological examination of brain tumor sections on day 21. Most likely since we had to use for the xenografts T-cell deficient nude mice, there was no significant difference whether the animals received stereotactically the adenovirus-or the HSV-1-based triple therapy. However in the triple therapy groups we observed periand intratumoral infiltrations of most likely macrophages and natural killer cells, but not in the untreated or temozolomide administered animals (data not shown). We did not observe any signs of encephalitis nor adenovirus or HSV-1 viremia by quantitative PCR (detection limit 500 Ad5 and HSV-1 DNA copies/ml serum).
Discussion
We compared side-by-side the anti-neoplastic efficacy of the targeted oncolytic HSV-1 vector G47D 23 with that of the double heterologous promoter controlled oncolytic adenoviral vector Ad5/35.GD Á Ki alone or in combination with FMG expression and/or chemotherapy.
The presence of coxsackie and adenovirus receptor (CAR), the primary cellular receptor of Ad5, and the capacity of Ad5 to infect human glioma cells has been questioned by several groups. [33] [34] [35] [36] [37] Previously, it has been demonstrated that the oncolytic efficacy of adenoviral vectors critically depends on their infection efficiency of the targeted tumor cells. 31, 32 Since CD46 is overexpressed by malignant glioma cells, 40 we analyzed the fiber chimeric Ad5/35, which uses CD46 as primary receptor to bypass the dependence on CAR for adenoviral entry and replication. 38, 39 In addition we evaluated Ad5/3 which uses CD80 73 but not CD46 as cellular attachment factor 39 and an Ad5-based vector with an RGD integrinbinding motif in the fiber knob. Of the tested vectors we observed with the Ad5/35-based vector the highest transduction efficiency of short-term cultures of glioblastoma cells. The transduction efficiency of the Ad5/35 vector was B70% higher when compared to the homologous vector with the native Ad5 fiber. Furthermore the differences among the tested glioblastoma cell lines and short-term cultures were relative low, in contrast to the other evaluated vectors. Also in other studies Ad5/35-based vectors have shown great promise, as they are able to transduce many human cell types, including human hematopoietic progenitor cells, human dendritic cells, and 
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primary human tumor cells, with greater efficiency than the parental Ad5 vectors. 74 The transduction efficiency of the Ad5/35 vector was similar to that of the neurotrophic HSV-1.
In glioblastoma the glial fibrillary acidic protein (GFAP) is in most cases at least focally detectable by immunohistochemistry and staining for pKi67, which is exclusively expressed in proliferating cells. 24 Therefore, we paid special attention to these promoters for the development of transcriptionally targeted oncolytic adenoviral vectors for glioblastoma therapy. Both, the evaluated adenovirus Ad5/35.GD Á Ki and the HSV-1 based vector G47D utilized the extraordinary circumstances of glioblastoma, where the surrounding tissue is post-mitotic, whereas the tumor itself is the only dividing tissue in the cranium. For this, the viral vectors failed to kill non-malignant neuronal cells and were only in tumor cells active. Our cytopathic effect assay demonstrated that Ad5/35.GD Á Ki lysed already at low MOI the tested proliferating glioblastoma cells presumably due to the specificity of the promoters driving viral replication. The G47D killed at low MOI proliferating glioblastoma as well as non-glioblastoma cells. Both viruses failed to generate plaques in non-proliferating cells, a requirement for safety.
Since our oncolytic adenovirus replicates in and lyses preferentially in proliferating GFAP-positive cells and the U251 cell line is the only permanent glioblastoma cell lines that has not lost GFAP expression 59 we used this cell line for our in vivo studies. We demonstrated, in subcutaneous U251 xenograft model that the oncolytic efficacy of the G47D vector was significantly greater than that of the tested conditionally replicative vector Ad5/ 35.GD Á Ki, alone or in combination with temozolomide.
Previously, we demonstrated that transcriptional targeting of adenoviral vectors does not influence their oncolytic efficacy in the target cells, when compared to the parental adenovirus (e.g. dl327).
30,60 Furthermore, Hitt et al. demonstrated that replication of adenovirus with E1A under the control of heterologous promoters is largely independent of the promoter strength. 75 This suggests that the enhanced efficacy of the HSV-1-when compared to the Ad.5/35-based vectors is most likely not caused by the transductional target approach. However, it should be taken into account that the adenoviral vector Ad5/35.GD Á Ki used in this study is E3-deleted to increase the packaging capacity of the vector for regulatory elements. Using the GFAP promoters in our transcriptional targeting strategy would have exceeded the packaging capacity of E1 and E3-positive adenoviral vectors. 51 Although the adenoviral E3-region is dispensable for the growth and propagation of adenovirus in cell culture, 76 deletion of the E3 region results in a reduced oncolytic efficacy of the vectors since the E3-11.6 kD gene product, which is required for efficient cells lysis and release of adenoviral progeny from infected cells, is missing. 77 Since chemotherapy is effective in only a minority of glioblastoma patients, we evaluated whether the expression of FMG in glioblastoma cells in combination with temozolomide chemotherapy causes synergistic cell killing, as observed in two previous studies using colorectal and pancreatic cancer cells. 49, 50 We qualitatively confirmed these studies in glioblastoma cells in vitro and in vivo. Despite the poor intratumoral transduction efficiency of the replication-defective vector Ad5/35.H/F we observed in the subcutaneous glioblastoma xenograft model in combination with temozolomide a significantly improved survival when compared to treatment with the individual compounds.
Since conditionally replicative adenoviral vectors can only carry relatively small therapeutic genes and a B6.4 kb FMG expression cassette would have clearly exceeded the packaging capacity of adenovirus, 51 we trans-complemented the replication-defective FMG encoding adenoviral vector with a helper virus (Ad5/35.GD Á Ki) to enhance tumor transduction efficiency. 52, 54, [56] [57] [58] As two vectors are necessary to transduce the same tumor cell (two-hit kinetic), the efficacy of this approach is lower than using an oncolytic vector encoding FMG (one-hit kinetic). 78 Thus, for direct comparison we trans-complemented the HSV.H/F vector with the respective oncolytic vector G47D vector, despite the fact that we have generated a HSV-1 vector encoding FMG. Otherwise a comparison of the two viral vector systems would be significantly hampered and would clearly favor the HSV-1 vector.
In the subcutaneous glioblastoma xenograft model we observed with the triple therapy consisting of FMG expression, chemotherapy, and trans-complementing oncolytic adenovirus or HSV-1 vectors strongly enhanced anti-neoplastic treatment efficacy. Also in the combined treatment the efficacy of the G47D vector alone or in combination with HSV.H/F and/or temozolomide was significantly greater than the corresponding adenovirusbased treatment. Neither in the subcutaneous nor in the intracranial glioblastoma xenograft model we observed with the triple therapy treatment related toxicity.
Several factors were responsible for this improved treatment efficacy that worked in concert: First, due to the trans-complementation strategy a greater percentage of the tumor cells expressed FMG. Second, oncolytic adenoviral or HSV-1-based vectors can enhance the efficacy of chemotherapeutic agents by themselves. 19, 79 Third, without using chemotherapy, several groups reported previously that the intratumoral expression of FMG enhances the efficacy of virotherapy. 42, 43, 47 Using colorectal cancer cells we demonstrated that the synergistic enhancement of chemotherapy in combination with FMG expression is independent of functional p53 and results in the induction of apoptosis via a mitochondrial death pathway controlled by Bcl-2 family proteins. 80 In summary, we demonstrated that a fiber chimeric Ad5/35 vector transduces significantly better short-term cultures of human glioblastoma cells than a homologous adenoviral vector with the native Ad5 fiber. The transduction efficiency of HSV-1 was similar to that of Ad5/35. We confirmed in glioblastoma in vitro and in vivo that the expression of measles virus fusogenic membrane proteins significantly enhances chemotherapy. The antineoplastic effect was superior when the FMG encoding vectors were trans-complemented for replication with their respective oncolytic vector. The treatment efficacy of the G47D vector alone or in the combination therapy was significantly greater than the corresponding adenovirusbased treatment. Our data clearly indicates that the intratumoral expression of fusogenic membrane proteins in combination with chemotherapy deserves further evaluation for cancer gene therapy.
